Modified T-Cells Penetrating Fugetactic Wall via AMD3100 Conjugate
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune cells, such as NK-cells and T-cells, face challenges in penetrating the fugetactic wall surrounding solid mass tumors due to CXCL12 overexpression, which also lacks tumor-specific targeting capabilities, leading to compromised directional guidance and therapeutic inefficacy.
Innovation Solution
Modification of immune cells with an AMD3100 conjugate containing a ligand for tumor-specific receptors, allowing them to penetrate through the fugetactic wall while imparting tumor-specific targeting by binding to CXCR4 receptors and incorporating folic or pteroic acid as targeting moieties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune cells are used to target tumors, then tumor-specific targeting is achieved, but the cells cannot penetrate the fugetactic wall due to CXCL12 overexpression
Solution Approach 1:
The patent uses AMD3100 as an intermediary substance that blocks the CXCL12-CXCR4 interaction. AMD3100 binds to CXCR4 receptors on immune cells, preventing CXCL12 from binding and creating the fugetactic wall. This mediator approach allows immune cells to penetrate the tumor microenvironment while maintaining their targeting capabilities through other mechanisms such as CAR modification.
2Object-affected harmful factors
If AMD3100 is used to block CXCL12 binding, then penetration through fugetactic wall is enabled, but directional guidance is lost
Solution Approach 1:
The patent combines multiple approaches: AMD3100 treatment to block CXCL12-mediated fugetaxis, along with CAR-T cell modification to provide new directional guidance through tumor-specific antigen recognition. The merging of these two mechanisms allows simultaneous penetration through the fugetactic wall and maintenance of targeting accuracy via the CAR receptor system.
3Reliability
If CAR-T cells are used for tumor targeting, then tumor-specific recognition is improved, but ability to penetrate fugetactic wall remains compromised
Solution Approach 1:
The patent employs AMD3100 as a mediator that specifically addresses the CXCL12-CXCR4 axis barrier. By blocking this particular interaction pathway, AMD3100 enables CAR-T cells to reach the tumor site without interfering with the CAR receptor's ability to recognize and bind to tumor-specific antigens, thus maintaining tumor-specific recognition while enabling penetration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the ability of immune cells to traverse through the tumor's fugetactic wall and provides specific targeting to cancer cells, improving therapeutic outcomes by reducing the fugetactic effect and enhancing the efficacy of cancer immunotherapies.
Implementation Method 1
CXCR4 receptors are expressed on many cellular surfaces including T-cells such as Teff and Treg cells, NK cells and the like. Under normal conditions, certain immune cells are able to follow a concentration gradient of CXCL12 that provides the necessary directional guidance. AMD3100 acts to inhibit solid mass tumor fugetaxis by interfering with the binding of CXCL12 to CXCR4 on T-cells.
Implementation Method 2
Under normal conditions, certain immune cells are able to follow a concentration gradient of CXCL12 that provides the necessary directional guidance so that these immune cells are delivered to sites of infection, inflammation, etc.
Implementation Method 3
as a defense mechanism, tumors, e.g., solid mass tumors, overexpress the cytokine CXCL12. Such creates a fugetactic wall around the tumor as the overexpression of CXCL12 sufficiently saturates the CXCR4 receptors on the such immune thereby 'blinding' the directional guidance.
Data Source
AI summary
Disclosed are modified T-cells so that the modified T-cells are capable of penetrating the fugetactic wall generated by tumors, including solid mass tumors, as well as imparting tumor specific targeting for these modified T-cells.